RT Journal Article
SR Electronic
T1 Prevalence of asymptomatic glioma and implications for survival
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20080564
DO 10.1101/2020.04.27.20080564
A1 Warren, Paula Province
A1 Lobbous, Mina
A1 Peeri, Noah C.
A1 Thompson, Zachary J.
A1 Thompson, Reid C.
A1 Olson, Jeffrey J.
A1 LaRocca, Renato V.
A1 Chowdhary, Sajeel A.
A1 Anderson, Mark D.
A1 Vogelbaum, Michael A.
A1 Markert, James M.
A1 Nabors, Louis B.
A1 Egan, Kathleen M.
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.27.20080564.abstract
AB Background Brain tumors can present as focal neurologic deficits (reflecting the tumor location) or generalized symptoms due to increased intracranial pressure. Occasionally, brain tumors can be found incidentally in asymptomatic patients or in patients with unrelated symptoms who undergo brain imaging. The term incidentaloma is used to refer to these imaging abnormalities.Objective The object of this study was to examine the prevalence and correlates of asymptomatic glioma in a large epidemiological study of brain tumors.Methods The analysis was based on a large series of patients with glioma (N = 1989) enrolled in a multicenter clinic-based epidemiologic study between 2005 and 2017. Patients were considered asymptomatic from the tumor, and thus as having an incidentally detected glioma (IDG), if the tumor was diagnosed during workup of injury or unrelated medical condition.Results A total of 32 of 1989 (1.6%) patients were asymptomatic at diagnosis. The leading indication for brain imaging in IDG was non-workplace injuries followed by medical workup for unrelated conditions. IDG was more prevalent in patients younger than 50 years of age (2.6% vs 1.0%). IDG was also more common in patients with low grade gliomas (4.7% for WHO grade II and 1.5% for WHO grade III) vs glioblastomas (0.6% in WHO grade IV).Conclusion The present data suggest that gliomas may be found incidentally, especially among low grade gliomas. Studies of IDG may be useful as a proxy for early detection of tumor as a means to improve patient survival.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed for this manuscript are not available for dissemination.